Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China. more
Time Frame | CPHI | Sector | S&P500 |
---|---|---|---|
1-Week Return | -22.97% | 0.31% | -1.26% |
1-Month Return | 20.6% | 0.6% | -4.16% |
3-Month Return | -19.53% | -9.44% | -0.46% |
6-Month Return | -24.17% | -5.15% | 3.58% |
1-Year Return | -57.9% | 0.33% | 22.47% |
3-Year Return | -99.08% | 4.53% | 25.13% |
5-Year Return | -98.75% | 35.98% | 77.7% |
10-Year Return | -98.71% | 100.72% | 190.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 10.92M | 10.87M | 9.64M | 8.10M | 7.01M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":99.47,"profit":true},{"date":"2021-12-31","value":88.26,"profit":true},{"date":"2022-12-31","value":74.19,"profit":true},{"date":"2023-12-31","value":64.18,"profit":true}] |
Cost of Revenue | 9.44M | 8.91M | 9.29M | 8.60M | 7.29M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":94.41,"profit":true},{"date":"2021-12-31","value":98.42,"profit":true},{"date":"2022-12-31","value":91.06,"profit":true},{"date":"2023-12-31","value":77.24,"profit":true}] |
Gross Profit | 1.48M | 1.95M | 349.27K | (493.92K) | (281.08K) | [{"date":"2019-12-31","value":75.9,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":17.88,"profit":true},{"date":"2022-12-31","value":-25.29,"profit":false},{"date":"2023-12-31","value":-14.39,"profit":false}] |
Gross Margin | 13.57% | 17.97% | 3.62% | (6.09%) | (4.01%) | [{"date":"2019-12-31","value":75.5,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":20.16,"profit":true},{"date":"2022-12-31","value":-33.91,"profit":false},{"date":"2023-12-31","value":-22.31,"profit":false}] |
Operating Expenses | 4.87M | 4.42M | 3.46M | 3.15M | 2.47M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":90.64,"profit":true},{"date":"2021-12-31","value":71.12,"profit":true},{"date":"2022-12-31","value":64.64,"profit":true},{"date":"2023-12-31","value":50.72,"profit":true}] |
Operating Income | (3.39M) | (2.46M) | (3.12M) | (3.55M) | (2.75M) | [{"date":"2019-12-31","value":-338958300,"profit":false},{"date":"2020-12-31","value":-245743200,"profit":false},{"date":"2021-12-31","value":-311572500,"profit":false},{"date":"2022-12-31","value":-354897700,"profit":false},{"date":"2023-12-31","value":-275182000,"profit":false}] |
Total Non-Operating Income/Expense | (17.61M) | (576.97K) | (1.08M) | (847.73K) | (701.45K) | [{"date":"2019-12-31","value":-1760665200,"profit":false},{"date":"2020-12-31","value":-57696800,"profit":false},{"date":"2021-12-31","value":-107793200,"profit":false},{"date":"2022-12-31","value":-84772800,"profit":false},{"date":"2023-12-31","value":-70144600,"profit":false}] |
Pre-Tax Income | (20.70M) | (2.87M) | (3.40M) | (3.97M) | (3.08M) | [{"date":"2019-12-31","value":-2070204400,"profit":false},{"date":"2020-12-31","value":-286677700,"profit":false},{"date":"2021-12-31","value":-339947600,"profit":false},{"date":"2022-12-31","value":-397284100,"profit":false},{"date":"2023-12-31","value":-307881800,"profit":false}] |
Income Taxes | 321.72K | 294.16K | 542.00K | 6.25M | (4.00) | [{"date":"2019-12-31","value":5.15,"profit":true},{"date":"2020-12-31","value":4.71,"profit":true},{"date":"2021-12-31","value":8.67,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (21.02M) | (3.16M) | (3.94M) | (10.22M) | (3.08M) | [{"date":"2019-12-31","value":-2102376200,"profit":false},{"date":"2020-12-31","value":-316093600,"profit":false},{"date":"2021-12-31","value":-394147700,"profit":false},{"date":"2022-12-31","value":-1022163500,"profit":false},{"date":"2023-12-31","value":-307881400,"profit":false}] |
Income From Continuous Operations | (20.70M) | (2.87M) | (3.40M) | (3.97M) | (3.11M) | [{"date":"2019-12-31","value":-2070204400,"profit":false},{"date":"2020-12-31","value":-286677700,"profit":false},{"date":"2021-12-31","value":-339947600,"profit":false},{"date":"2022-12-31","value":-397284100,"profit":false},{"date":"2023-12-31","value":-311078900,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (21.02M) | (3.16M) | (3.94M) | (10.22M) | (3.08M) | [{"date":"2019-12-31","value":-2102376200,"profit":false},{"date":"2020-12-31","value":-316093600,"profit":false},{"date":"2021-12-31","value":-394147700,"profit":false},{"date":"2022-12-31","value":-1022163500,"profit":false},{"date":"2023-12-31","value":-307881800,"profit":false}] |
EPS (Diluted) | (0.64) | (0.09) | (0.08) | (0.26) | (0.77) | [{"date":"2019-12-31","value":-64,"profit":false},{"date":"2020-12-31","value":-9.32,"profit":false},{"date":"2021-12-31","value":-8,"profit":false},{"date":"2022-12-31","value":-26,"profit":false},{"date":"2023-12-31","value":-76.92,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CPHI | |
---|---|
Cash Ratio | 0.15 |
Current Ratio | 0.79 |
Quick Ratio | 0.26 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CPHI | |
---|---|
ROA (LTM) | -17.54% |
ROE (LTM) | -74.89% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CPHI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.52 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.48 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CPHI | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.62 |
P/B | 0.59 |
Price/FCF | NM |
EV/R | 1.29 |
EV/Ebitda | NM |
PEG | NM |
China Pharma Holdings Inc (CPHI) share price today is $0.2002
Yes, Indians can buy shares of China Pharma Holdings Inc (CPHI) on Vested. To buy China Pharma Holdings Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CPHI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of China Pharma Holdings Inc (CPHI) via the Vested app. You can start investing in China Pharma Holdings Inc (CPHI) with a minimum investment of $1.
You can invest in shares of China Pharma Holdings Inc (CPHI) via Vested in three simple steps:
The 52-week high price of China Pharma Holdings Inc (CPHI) is $0.6. The 52-week low price of China Pharma Holdings Inc (CPHI) is $0.13.
The price-to-earnings (P/E) ratio of China Pharma Holdings Inc (CPHI) is
The price-to-book (P/B) ratio of China Pharma Holdings Inc (CPHI) is 0.59
The dividend yield of China Pharma Holdings Inc (CPHI) is 0.00%
The market capitalization of China Pharma Holdings Inc (CPHI) is $3.85M
The stock symbol (or ticker) of China Pharma Holdings Inc is CPHI